+

WO2010037042A3 - Procédés pour détecter et traiter le cancer - Google Patents

Procédés pour détecter et traiter le cancer Download PDF

Info

Publication number
WO2010037042A3
WO2010037042A3 PCT/US2009/058636 US2009058636W WO2010037042A3 WO 2010037042 A3 WO2010037042 A3 WO 2010037042A3 US 2009058636 W US2009058636 W US 2009058636W WO 2010037042 A3 WO2010037042 A3 WO 2010037042A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
detecting
treating cancer
treatment
neoplasia
Prior art date
Application number
PCT/US2009/058636
Other languages
English (en)
Other versions
WO2010037042A2 (fr
Inventor
Mark C. Poznansky
Hajah Siti Fatimah Jaafar
Dulcie V. Coleman
Pierre Leblanc
Original Assignee
The General Hospital Corporation
Imperial College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The General Hospital Corporation, Imperial College London filed Critical The General Hospital Corporation
Priority to US13/119,663 priority Critical patent/US9229004B2/en
Publication of WO2010037042A2 publication Critical patent/WO2010037042A2/fr
Publication of WO2010037042A3 publication Critical patent/WO2010037042A3/fr
Priority to US14/962,311 priority patent/US9885720B2/en
Priority to US15/888,662 priority patent/US11029313B2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4 or KC
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne généralement des compositions et des procédés pour le diagnostic, le traitement, et la surveillance d’une néoplasie chez un sujet, ainsi que des procédés de sélection de traitement.
PCT/US2009/058636 2008-09-26 2009-09-28 Procédés pour détecter et traiter le cancer WO2010037042A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US13/119,663 US9229004B2 (en) 2008-09-26 2009-09-28 Methods for detecting and treating cancer
US14/962,311 US9885720B2 (en) 2008-09-26 2015-12-08 Methods for detecting and treating cancer
US15/888,662 US11029313B2 (en) 2008-09-26 2018-02-05 Method of treating cervical neoplasia in patients infected with human papilloma virus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10052608P 2008-09-26 2008-09-26
US61/100,526 2008-09-26

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/119,663 A-371-Of-International US9229004B2 (en) 2008-09-26 2009-09-28 Methods for detecting and treating cancer
US14/962,311 Continuation US9885720B2 (en) 2008-09-26 2015-12-08 Methods for detecting and treating cancer

Publications (2)

Publication Number Publication Date
WO2010037042A2 WO2010037042A2 (fr) 2010-04-01
WO2010037042A3 true WO2010037042A3 (fr) 2010-05-27

Family

ID=42060432

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/058636 WO2010037042A2 (fr) 2008-09-26 2009-09-28 Procédés pour détecter et traiter le cancer

Country Status (2)

Country Link
US (2) US9229004B2 (fr)
WO (1) WO2010037042A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012047339A2 (fr) * 2010-06-28 2012-04-12 The General Hospital Corporation Anti-cxcr4 en tant que sensibilisant à des agents de traitement d'un cancer
WO2014138507A1 (fr) * 2013-03-06 2014-09-12 C & C Biopharma, Llc Traitement du cancer du col de l'utérus et/ou du cancer de l'ovaire à l'aide d'un modulateur de facteur de transcription
US9775816B2 (en) 2013-11-07 2017-10-03 The General Hospital Corporation Eluting matrix and uses thereof
WO2015152609A1 (fr) * 2014-03-31 2015-10-08 연세대학교 산학협력단 Composition antitumorale contenant un gène du gm-csf, un gène de la décorine, un arnsh inhibant l'expression du tgf-β2 et un arnsh inhibant l'expression de la foxp3
CA2999756A1 (fr) * 2015-09-24 2017-03-30 The University Of North Carolina At Chapel Hill Methodes et compositions pour reduire les metastases
CN110357946B (zh) * 2016-10-18 2021-08-03 国家纳米科学中心 一种抑制肿瘤转移的多肽及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007112330A2 (fr) * 2006-03-24 2007-10-04 Diadexus, Inc. Compositions et méthodes pour détecter, pronostiquer et traiter un cancer du côlon

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006128141A2 (fr) 2005-05-27 2006-11-30 Sirna Therapeutics, Inc. Inhibition, mediee par l'interference d'arn, de l'expression genique du facteur 1 derive des cellules stromales (sdf-1), au moyen d'acide nucleique interferant court (sina)
ES2385924T3 (es) * 2006-02-02 2012-08-03 Allergan, Inc. Inhibidores de la actividad de CXCR4 para su uso en el tratamiento de trastornos oculares
US7598028B2 (en) * 2006-11-28 2009-10-06 The Regents Of The University Of Michigan Compositions and methods for detecting and treating prostate disorders
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007112330A2 (fr) * 2006-03-24 2007-10-04 Diadexus, Inc. Compositions et méthodes pour détecter, pronostiquer et traiter un cancer du côlon

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE UNIPROTKB [online] 1 February 1996 (1996-02-01), "Stromal cell-derived factor 1.", Database accession no. P48061 *
JAFFAR ET AL.: "Correlation of CXCL12 expression and FoxP3+ cell infiltration with human papillomavirus infection and clinicopathological progression of cervical cancer.", AMER J PATHOL, vol. 175, no. 4, October 2009 (2009-10-01), pages 1525 - 1535 *
KODAMA ET AL.: "Association of CXCR4 and CCR7 chemokine receptor expression and lymph node metastasis in human cervical cancer.", ANN ONCOL JANUARY, vol. 18, no. 1, 2007, pages 70 - 76 *
KRYCZEK ET AL.: "Accumulation of CD45RO+ cells in peritoneal carcinomatous fluid favours survival of ovarian carcinoma patients.", CANCER IMMUNOL IMMUNOTHER, vol. 51, no. 9, November 2002 (2002-11-01), pages 513 - 519 *
SCOTTON ET AL.: "Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer.", CANCER RES, vol. 62, no. 20, 15 October 2002 (2002-10-15), pages 5930 - 5938 *
YU ET AL.: "Identification and expression of novel isoforms of human stromal cell-derived factor 1.", GENE, vol. 374, 7 June 2006 (2006-06-07), pages 174 - 179 *

Also Published As

Publication number Publication date
US20110287949A1 (en) 2011-11-24
WO2010037042A2 (fr) 2010-04-01
US9229004B2 (en) 2016-01-05
US9885720B2 (en) 2018-02-06
US20160320396A1 (en) 2016-11-03

Similar Documents

Publication Publication Date Title
WO2011037643A3 (fr) Compositions et procédés de détection et de traitement de carcinomes de la prostate
WO2008088858A3 (fr) Compositions et procédés comprenant des microarn pour traiter une néoplasie
WO2010062377A3 (fr) Procédés et compositions pour la détection et le traitement de l’éclampsie
WO2009108860A8 (fr) Procédés et compositions à base de micro-arn permettant de diagnostiquer, de pronostiquer et de traiter des troubles liés à la prostate
WO2010017515A3 (fr) Marqueurs spécifiques du cancer du sein et procédés d’utilisation
WO2010065630A3 (fr) Compositions et procédés de traitement d'une néoplasie hépatique
EP2179037A4 (fr) Procédés permettant un diagnostic, un pronostic et procédés de traitement
WO2009111643A3 (fr) Marqueurs microrna pour la récurrence d’un cancer colorectal
WO2012068400A3 (fr) Micro-arn utilisés comme biomarqueurs pour faire la distinction entre des néoplasmes thyroïdiens bénins et malins
WO2008153705A3 (fr) Procédés de traitement, de diagnostic et de détection de troubles liés à fgf21
WO2010083385A3 (fr) Composés permettant de réduire la résistance aux médicaments et leurs utilisations
ZA201101814B (en) Prevention, treatment and diagnosis of p.gingivalis infection
WO2010056737A3 (fr) Procédés et compositions impliquant des miarn dans des cellules souches cancéreuses
WO2012054638A3 (fr) Systèmes et procédés nmr pour la détection d'analytes
WO2009129246A3 (fr) Compositions et leurs procédés de préparation et d'utilisation
WO2008091692A3 (fr) Procédés de diagnostic, de traitement et de prévention de la perméabilité vasculaire accrue
WO2011073279A3 (fr) Procédé de traitement cosmétique impliquant un composé apte à condenser in situ
ZA200808669B (en) Methods of treating, diagnosing or detecting cancer
WO2010059242A3 (fr) Compositions diagnostiques de maladie neurodégénérative et procédés d'utilisation
IL207811A0 (en) Kit, composition, product or medicament for treating cognitive impairment
WO2012017430A3 (fr) Profils de micro-arn destinés au diagnostic, au pronostic et au traitement d'un mélanome
WO2007123722A3 (fr) Procedes de prevision et de pronostic de cancer, et surveillance d'une therapie anticancereuse
WO2010101793A3 (fr) Méthodes et compositions pour le diagnostic, le pronostic et le traitement du cancer
WO2010037042A3 (fr) Procédés pour détecter et traiter le cancer
MY155340A (en) Use of cathepsin c

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09817005

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13119663

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 09817005

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载